Last Updated: 17/06/2026

Optimisation of a potent and fast acting antimalarial class that is orally efficacious in vivo

Objectives

This project aims to to further develop an identified highly active antimalarial series to meet the prerequisites required for partnership with the Medicines for Malaria Venture (MMV) for progression into the clinic.

Principal Investigators / Focal Persons

Brad Sleebs

Rationale and Abstract

Malaria is a devastating disease that results in 600 000 deaths annually. Current therapeutics used to combat malaria have a limited duration of use in the clinic due to the onset of resistance. 

Date

Jan 2018 — Dec 2019

Total Project Funding

$493,027

Country / Project Site(s)

Australia

SHARE
SHARE